WebNov 10, 2024 · “I was inspired by people like Bob Swanson, the Founder of Genentech, who not coincidentally was our first angel investor at Cytokinetics. ... Cytokinetics is a leader in a specific area of biology … WebApr 2, 2024 · Apr. 02, 2024 9:50 AM ET Cytokinetics, Incorporated (CYTK) BMY Stephen Ayers 4.05K Follower s Summary Cytokinetics has developed aficamten, a drug for treating hypertrophic cardiomyopathy...
PRESS RELEASES Cytokinetics, Inc.
WebJul 1, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential... WebApr 10, 2024 · It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated CYTK. Shares of the company have moved down 20.5% compared with the industry’s decline of 4.7%. reaches of the kingdom
Cytokinetics To Participate In The 22nd Annual Needham
WebFounded Date 1998 Founders James Sabry, James Spudich, Lawrence Goldstein, Ronald Vale Operating Status Active Last Funding Type Post-IPO Debt Legal Name Cytokinetics, Inc. Stock Symbol NASDAQ:CYTK … Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998. Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. … See more Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases … See more Omecamtiv mecarbil, a cardiac muscle activator for the potential treatment of heart failure. In May 2024, omecamtiv mecarbil was granted fast track designation by the FDA for … See more Official website See more WebJul 1, 2024 · SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $450.0 million aggregate... reaches of the yangtze river